Clinical Trial Update: Clinical Trial Designed to Determine the Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy [Phase 2]

View source ↗

Summary

The Phase 2 trial of EMA401 for painful diabetic neuropathy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Neuropathy
• Painful Diabetic Neuropathy

Drugs mentioned

• EMA401

Snippet

Sponsor: Spinifex Pharmaceuticals Pty Ltd | Conditions: Diabetic Neuropathies | Phase 2 | Status: WITHDRAWN